000			02024 a2200493 4500
005			20250518084840.0
264		0	_c20211004
008			202110s 0 0 eng d
022			_a1744-8352
024	7		_a10.1080/14737159.2020.1728256 _2doi
040			_aNLM _beng _cNLM
100	1		_aShimazawa, Rumiko
245	0	0	_aRegulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. _h[electronic resource]
260			_bExpert review of molecular diagnostics _c06 2020
300			_a601-610 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aB7-H1 Antigen _xantagonists & inhibitors
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aDNA Mutational Analysis _xeconomics
650	0	4	_aDatabases, Nucleic Acid
650	0	4	_aDevice Approval _xlegislation & jurisprudence
650	0	4	_aDirect-To-Consumer Screening and Testing _xeconomics
650	0	4	_aDrug Resistance, Microbial _xgenetics
650	0	4	_aEquipment and Supplies _xclassification
650	0	4	_aGenetic Diseases, Inborn _xdrug therapy
650	0	4	_aGovernment Agencies _xorganization & administration
650	0	4	_aHealth Services Needs and Demand
650	0	4	_aHigh-Throughput Nucleotide Sequencing _xeconomics
650	0	4	_aHumans
650	0	4	_aImmune Checkpoint Inhibitors _xpharmacology
650	0	4	_aJapan
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMedical Device Legislation
650	0	4	_aMolecular Diagnostic Techniques _xeconomics
650	0	4	_aMolecular Targeted Therapy
650	0	4	_aMutation
650	0	4	_aNational Health Programs
650	0	4	_aNeoplasm Proteins _xantagonists & inhibitors
650	0	4	_aNeoplasms _xdrug therapy
650	0	4	_aPrecision Medicine _xmethods
700	1		_aIkeda, Masayuki
773	0		_tExpert review of molecular diagnostics _gvol. 20 _gno. 6 _gp. 601-610
856	4	0	_uhttps://doi.org/10.1080/14737159.2020.1728256 _zAvailable from publisher's website
999			_c30641352 _d30641352